...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medicine. >Evaluation of Intravitreal Ranibizumab on the Surgical Outcome for Diabetic Retinopathy With Tractional Retinal Detachment
【24h】

Evaluation of Intravitreal Ranibizumab on the Surgical Outcome for Diabetic Retinopathy With Tractional Retinal Detachment

机译：玻璃体腔内雷珠单抗对伴有牵引性视网膜脱离的糖尿病性视网膜病变的手术效果的评估

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study aims to investigate intravitreal injection of Ranibizumab on the surgical outcome for diabetic patients who had tractional retinal detachment but did not receive any preoperative retinal photocoagulation.Ninety-seven patients (97 eyes) who had diabetic retinopathy with tractional retinal detachment were enrolled to receive 23-G pars plana vitrectomy (PPV). They were assigned to an experimental group (Group I, n=47 eyes) and a control group (Group II, n=50 eyes). The patients in Group I were given 1 injection of intravitreal Ranibizumab (Lucentis 0.5mg/0.05mL) 1 week before surgery, whereas those in Group II went down to surgery directly. Follow-ups were performed for 6 months to 3 years (166 months), and indicators observed included postoperative best-corrected visual acuity, complications, and retinal thickness in the macula measured by optical coherence tomography.In Group I, BCVA improved from logMAR 1.92 +/- 0.49 to logMAR 0.81 +/- 0.39 following surgery, whereas in Group II, BCVA improved from logMAR 1.91 +/- 0.49 to logMAR 0.85 +/- 0.41. There was significant postoperative gain in vision, but there was no significant difference between the 2 groups at postoperative follow-up visits. The mean duration of vitrectomy in Group I and Group II was (40 +/- 7)minutes and (53 +/- 9)minutes, respectively, with significant difference. Iatrogenic breaks were noted in 5 eyes (11%) in the experimental group and 17 eyes (34%) in the control group; the difference was significant. The retinal thickness in the macula measured by OCT was (256 +/- 44) m and (299 +/- 84) m in Group I and Group II respectively with significant difference. Besides, there were significantly more eyes in Group II that required silicone oil tamponade and postoperative retinal photocoagulation.23-G PPV combined with intravitreal tamponade and panretinal photocoagulation still remains an effective regimen for the treatment of diabetic retinopathy complicated with tractional retinal detachment. Preoperative intravitreal injection of Ranibizumab could shorten surgical duration, reduce intraoperative complications, and sometimes spare the need for silicone oil tamponade and postoperative retinal photocoagulation, alleviating patients' suffering from surgery.
机译：本研究旨在探讨雷珠单抗的玻璃体内注射对患有牵引性视网膜脱离但未接受任何术前视网膜光凝治疗的糖尿病患者的手术结局的影响。研究纳入了97例（97眼）患有糖尿病性视网膜病变并伴有牵引性视网膜脱离的糖尿病患者。 23-G pars平板玻璃体切除术（PPV）。将他们分为实验组（I组，n = 47眼）和对照组（II组，n = 50眼）。第一组患者在手术前1周注射1剂玻璃体内雷珠单抗（Lucentis 0.5mg / 0.05mL），而第二组患者直接接受手术治疗。随访时间为6个月至3年（166个月），观察指标包括术后最佳矫正视力，并发症和通过光学相干断层扫描测量的黄斑视网膜厚度。在第一组，BCVA从logMAR 1.92改善。手术后+/- 0.49至logMAR 0.81 +/- 0.39，而在第二组中，BCVA从logMAR 1.91 +/- 0.49改善至logMAR 0.85 +/- 0.41。术后视力有显着提高，但两组术后随访时无显着差异。第一组和第二组的玻璃体切除术的平均持续时间分别为（40 +/- 7）分钟和（53 +/- 9）分钟，差异有统计学意义。实验组有5只眼（11％）和对照组有17只眼（34％）出现了医源性断裂。差异很大。通过OCT测量的黄斑的视网膜厚度在第一组和第二组中分别为（256 +/- 44）m和（299 +/- 84）m，具有显着差异。此外，第二组中有更多的眼睛需要硅油填塞和术后视网膜光凝.23-G PPV联合玻璃体内填塞和全视网膜光凝仍然是治疗糖尿病性视网膜病变并发视网膜脱离的有效方案。术前玻璃体内注射雷珠单抗可以缩短手术时间，减少术中并发症，有时无需硅油填塞和术后视网膜光凝，从而减轻了患者的手术痛苦。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号